Drug intelligence / Profile preview

compound zhuye shigao

Development stage: Preclinical
Lead developer: Chinese PLA General Hospital
Administration: Oral

Overview

Compound Zhuye Shigao is a Traditional Chinese Medicine (TCM) formulation, typically prepared as a granule, based on the classic Zhuye Shigao Tang. Its primary active components include *Lophatherum gracile* (bamboo leaf) and *Gypsum fibrosum* (gypsum). The preparation is used in clinical practice to treat inflammatory conditions of the upper respiratory and oral mucosa, specifically recurrent oral ulcers and chronic pharyngitis. It functions by clearing internal heat and promoting fluid production. Clinical research, including studies conducted by the PLA General Hospital, evaluates its efficacy in reducing pain and promoting mucosal healing.

Other names: Zhuye Shigao TangZhuye Shigao granuleFufang Zhuye Shigao KeliCompound Zhuye Shigao granule

Beyond the preview

Go deeper on compound zhuye shigao.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound zhuye shigao.

Explore the full profile